GlassScriptPhysician profile
Cherry Lou C Rudge
NPI 1336547256
$28,329.70
in general payments reported to CMS, 2019-2025
29 companies · $3,375 in 2025
The $3,375 reported for 2025 was more than what 97% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $251 · 2022: $2,878 · 2023: $6,150 · 2024: $16K · 2025: $3,375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Food and Beverage: $6,083 · Travel and Lodging: $1,079 · Education: $186 · Consulting Fee: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,737.50 |
| Food and Beverage | $6,082.52 |
| Travel and Lodging | $1,078.81 |
| Education | $185.95 |
| Consulting Fee | $115.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $23,913.71 | 2022-2025 | Darzalex, Tecvayli, Carvykti |
| E.R. Squibb & Sons, L.L.C. | $747.55 | 2022-2024 | Reblozyl, Pomalyst |
| Astellas Pharma US INC | $503.94 | 2021-2024 | Padcev, Xtandi, Xospata |
| Astrazeneca Pharmaceuticals LP | $470.29 | 2022-2024 | Calquence |
| Janssen Scientific Affairs, LLC | $428.33 | 2023-2024 | Talvey, Imbruvica, Tecvayli |
| Glaxosmithkline, LLC. | $397.35 | 2021-2025 | Ojjaara, Jemperli |
| Pfizer INC. | $367.14 | 2024 | |
| Novartis Pharmaceuticals Corporation | $203.29 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $139.46 | 2021-2024 | |
| Amgen INC. | $125.00 | 2022 | |
| Agios Pharmaceuticals, INC. | $124.96 | 2025 | Pyrukynd |
| Stemline Therapeutics INC. | $120.39 | 2024 | Orserdu |
| Secura Bio, INC. | $104.10 | 2024 | Copiktra |
| Emd Serono, INC. | $94.72 | 2023 | Bavencio |
| Merck Sharp & Dohme LLC | $91.21 | 2021-2024 | Lynparza, Keytruda |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $90.95 | 2024 | |
| Celgene Corporation | $80.20 | 2022-2024 | Pomalyst, Opdualag, Reblozyl |
| Genzyme Corporation | $78.67 | 2024 | |
| Abbvie INC. | $73.10 | 2021-2025 | |
| Incyte Corporation | $38.77 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.18 | 2023 | Fruzaqla |
| Global Blood Therapeutics, INC. | $15.41 | 2021 | |
| Eisai INC. | $14.55 | 2021 | |
| Servier Pharmaceuticals LLC | $14.43 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $13.97 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $13.35 | 2022 | |
| Daiichi Sankyo INC. | $12.72 | 2021 | |
| Lilly USA, LLC | $12.57 | 2021 | |
| Heron Therapeutics, INC. | $12.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cherry Lou Rudge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.